Skip to main content

Table 1 Patient demographics and disease characteristics

From: PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer

Variable

All patients (n = 208)

No.

%

Age, years

 Median

58

 

 Range

29–82

Sex

 Male

136

65.4

 Female

72

34.6

Smoking status

 Current

73

35.1

 Former

58

27.9

 Never

77

37.0

Histology

 Adenocarcinoma

164

78.8

 Squamous cell

32

15.4

 Other

12

5.8

Stage

 IIIB

15

7.2

 IV

193

92.8

ECOG PS

 0

17

8.2

 1

134

64.4

 2

57

27.4

First-line therapy

 GP

105

50.5

 IP

103

49.5

Salvage EGFR-TKI therapy

 Second-line

60

28.8

 Third-line

38

18.3

 No

110

52.9

EGFR mutations

 19DEL

38

18.3

 L858R

13

6.3

 Wild type

143

68.7

 Not determined

14

6.7

KRAS mutations

 Codon 12

8

3.8

 Codon 13

2

1.0

 Codon 61

2

1.0

 Wild type

123

59.1

 Not determined

73

35.1

  1. EGFR-TKI: epidermal growth factor receptor-tyrosine kinase inhibitor